Method for taking molecular marker in diagnosis and prognosis evaluation of breast cancer

Abstract

The invention relates to a method for taking the breast cancer molecular marker S100A8 / A9 in diagnosis and prognosis evaluation of the breast cancer. According to the method, results show that the expression indexes of the molecular marker S100A8 / A9 in breast cancer patients with different molecular pathological subtypes are different, that is, thesubtypemolecular marker S100A8 / A9 is highly expressed in a substrate cellular type (basal-like) breast cancer patient and a Her-2 amplified) overexpression type breast cancer patient, but is relatively low in expression index in a lumen epithelia A type (Luminal A) breast cancer patient and a lumen epithelia B type (Luminal B) subtype breast cancer patient, that is, the statistic difference is obvious. For published NKI breast cancer chip data, patients are divided into a high group and a low group based on S100A8 / A9 for Kaplan-Meier survivorship curve analysis, results show that the negative correlation between the S100A9 expression level and the total survival rate is obvious, the prognosis of a breast cancer patient with high S100A9 expression is poor, and the prognosis application value of prompting breast cancer is high.

Description

technical field [0001] The invention belongs to the field of biotechnology and medicine, and relates to a method for molecular markers for breast cancer diagnosis and prognosis assessment. Background technique [0002] Breast cancer is one of the most common malignant tumors in women, accounting for 7-10% of all kinds of malignant tumors in the whole body, ranking first in the incidence of malignant tumors in women. In the past ten years, the incidence of breast cancer in my country has been increasing year by year, and the age of onset tends to be younger, which has seriously threatened the health of women in our country. Breast cancer is a highly molecularly heterogeneous disease, and the traditional anatomical staging and histological classification can no longer meet its current clinical diagnosis and treatment needs, especially the lack of breast cancer histological classification that can mark tumor biological behavior and provide guidance for clinical treatment met...

AI Technical Summary

Problems solved by technology

Breast cancer is a highly molecularly heterogeneous disease, and the traditional anatomical staging and histological classification can no longer meet its current clinical diagnosis and treatment needs, especially the lack of breast cancer histological classification that can mark tumor biological behavior and provide guidance for clinical treatment method

However, there is no report on its application in the diagnosis and prognosis of breast cancer

Images